Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant COVID-19 bivalent xbb+prototype protein vaccine
- Development stage
- Phase 2
- Lead developer
- WestVac Biopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
WSK-V101C is a recombinant COVID-19 bivalent protein vaccine developed using the Sf9 cell line. It targets SARS-CoV-2 by presenting both the XBB variant and prototype spike proteins to elicit an immune response. The vaccine is designed as a booster to enhance immunogenicity against emerging variants of SARS-CoV-2, with clinical trials evaluating its safety and immunogenicity in adults aged 18 years and older[2][3]. It falls under the category of biologic drugs derived from living organisms[1].
- Other names
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine Sf9 CellWSK-V101WSK-V-101WSK-V 101
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Recombinant COVID-19 bivalent xbb+prototype protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant COVID-19 bivalent xbb+prototype protein vaccine.